Positive Choice: Prevention for Positive Health
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00447707 |
Recruitment Status
:
Completed
First Posted
: March 15, 2007
Last Update Posted
: January 12, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections Sexual Risk Behavior Substance Use Risks | Behavioral: Positive Choice | Not Applicable |
A preliminary analysis of baseline data was conducted in January 2006, which indicated that the Positive Choice intervention achieved significant reductions in drug use. These findings were reported in a poster presentation at the XVI International AIDS Conference in Toronto, Canada, in August 2006. A final analysis of outcomes data was conducted in fall 2006 (September - December). Aggregate results from all five study sites are summarized below.
We found a high prevalence of risky behaviors in our sample (497/918, or 54%) and achieved high retention for follow-up in both groups (>80%). We found significant elimination of any drug use in the intervention group at both follow-ups. Among all participants who reported drug use at baseline, 66% of intervention participants continued their drug use at 3-month follow-up compared to 85% of control participants (OR 0.356, p<0.01). At 6-month follow-up, 59% of intervention participants continued their drug use compared to 88% of the control group (<0.001). Among participants who reported methamphetamine use at baseline, 58% continued their methamphetamine use at 3-month follow-up compared to 83% of control participants (OR 0.285, p=0.02). At 6-month follow-up, 53% of intervention participants continued their methamphetamine use compared to 73% of the control group (OR 0.344, p=0.03). We also found significantly less unprotected sex with casual partners by intervention participants at 3-month follow up (69% vs. 87%, OR 0.313, p=0.04), and fewer intervention participants who exceeded the recommended number of drinks per week at 3-months (53% vs. 78%, OR 0.310, p=0.02) Our findings indicate that the Positive Choice program was effective at reducing important behavioral risks among HIV-positive adults in care. Positive Choice is an appropriate and effective adjunct to routine medical care for HIV-positive adults.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 497 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single |
Official Title: | Positive Choice: Prevention for Positive Health |
Study Start Date : | December 2003 |
Study Completion Date : | September 2006 |

- Elimination of risky drinking, illicit alcohol use, unprotected sex, and non-disclosure of HIV status to sex partners.
- Measures of change in risky alcohol use, illicit drug use, unprotected sex, and non-disclosure of HIV status to sex partners.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- 18 years or older,
- HIV-positive 3 months or longer,
- English speaking; and
- Receiving medical care at a participating clinic.
Exclusion Criteria:
- Less than 18 years old,
- HIV-positive less than 3 months,
- Non-English speaking; and
- Not receiving medical care at a participating clinic.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00447707
United States, California | |
Adult Immunology Clinic, Highland Hospital | |
Oakland, California, United States, 94602 | |
AIDS Project East Bay (APEB) | |
Oakland, California, United States, 94607 | |
East Bay AIDS Center (EBAC), Alta Bates Hospital | |
Oakland, California, United States, 94609 | |
Kaiser Permanente Medical Center | |
San Francisco, California, United States, 94115 | |
Adult Immunology Clinic, Fairmont Hospital | |
San Leandro, California, United States, 94578 |
Principal Investigator: | Barbara Gerbert, PhD | University of California, San Francisco |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00447707 History of Changes |
Other Study ID Numbers: |
R01DA015016 ( U.S. NIH Grant/Contract ) |
First Posted: | March 15, 2007 Key Record Dates |
Last Update Posted: | January 12, 2017 |
Last Verified: | March 2007 |
Keywords provided by National Institute on Drug Abuse (NIDA):
Substance use Unprotected sex Behavioral intervention |
HIV care Prevention with Positives HIV seronegativity |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |